Orthopediatrics (KIDS) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of Orthopediatrics (NASDAQ:KIDS) from a hold rating to a buy rating in a research note released on Saturday. They currently have $46.00 price objective on the stock.

According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “

A number of other brokerages also recently weighed in on KIDS. BidaskClub upgraded Orthopediatrics from a buy rating to a strong-buy rating in a report on Friday, March 1st. BTIG Research lifted their price target on Orthopediatrics to $44.00 and gave the company a buy rating in a report on Friday, March 8th. Finally, JMP Securities assumed coverage on Orthopediatrics in a report on Wednesday, February 20th. They set an outperform rating and a $44.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Orthopediatrics presently has an average rating of Buy and a consensus price target of $41.00.

Shares of KIDS stock opened at $43.43 on Friday. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $44.25. The company has a current ratio of 10.54, a quick ratio of 7.77 and a debt-to-equity ratio of 0.26. The firm has a market cap of $597.36 million, a PE ratio of -45.24 and a beta of 0.18.

Orthopediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). Orthopediatrics had a negative return on equity of 22.99% and a negative net margin of 20.89%. The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $14.50 million. During the same quarter in the previous year, the company posted ($1.41) earnings per share. Orthopediatrics’s revenue for the quarter was up 24.8% compared to the same quarter last year. On average, equities research analysts anticipate that Orthopediatrics will post -0.41 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. acquired a new stake in Orthopediatrics during the fourth quarter valued at $3,880,000. Geode Capital Management LLC boosted its position in Orthopediatrics by 51.9% during the fourth quarter. Geode Capital Management LLC now owns 80,310 shares of the company’s stock valued at $2,801,000 after purchasing an additional 27,429 shares during the last quarter. FMR LLC boosted its position in Orthopediatrics by 8.6% during the fourth quarter. FMR LLC now owns 414,600 shares of the company’s stock valued at $14,462,000 after purchasing an additional 33,000 shares during the last quarter. RTW Investments LP acquired a new stake in Orthopediatrics during the fourth quarter valued at $7,848,000. Finally, Prospect Capital Advisors LLC acquired a new stake in Orthopediatrics during the fourth quarter valued at $7,136,000. 51.70% of the stock is owned by hedge funds and other institutional investors.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Read More: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply